Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 46

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 46
---

    of June 30, 2025 and December 31, 2024, the Company had 200,000,000 shares of common stock authorized and 604,963 and 428,799 shares
    issued and outstanding, respectively. As of June 30, 2025 and December 31, 2024, the Company had 5,000,000 shares of preferred stock
    authorized. There were no shares of preferred stock issued or outstanding as of June 30, 2025 and December 31, 2024. As of June 30,
    2025 and December 31, 2024, there were warrants outstanding to purchase an aggregate of 312,354 and 238,423 shares of common stock,
    respectively. As of June 30, 2025, these warrants were exercisable at a weighted average price of $127.05 and their weighted average
    remaining contractual term was 3.5 years.

    F-9

    b.
    On
    January 16, 2025, the Company completed a private placement offering pursuant to which the Company sold and issued to certain investors
    an aggregate of 75,335 shares of common stock and warrants to purchase 75,335 shares of common stock (the “January 2025 Warrants”).
    The shares and January 2025 Warrants were sold on a combined basis for consideration of $29.82 for one share and one January 2025
    Warrant. The January 2025 Warrants are immediately exercisable at an exercise price of $26.32 per share and expire five years from
    the date of issuance. The total net proceeds were approximately $2.0 million, after deducting placement agent and other offering
    expenses in the amount of approximately $0.25 million. In February 2025, the Company filed a registration statement to register the
    resale by the investors of the shares of common stock and shares of common stock issuable upon exercise of the January 2025 Warrants.
    The registration statement was declared effective on February 11, 2025. In addition, in connection with the January 2025 Offering,
    the Company issued to the placement agent and its designees warrants to purchase an aggregate of 5,268 shares of common stock at
    an exercise price of $32.90. The placement agent warrants are exercisable six months from the date of issuance and expire on the fifth